IL1B and chronic kidney disease: This suggests that the observed PBUTs-mediated interplay between pro-inflammatory and oxidative signaling pathways in the proximal tubule leads to IL-1β release, which could potentially be exploited for specific treatments aimed at contrasting CKD-associated inflammation.